STOCK TITAN

Brainsway Ltd. (BWAY) Stock News

BWAY NASDAQ

BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.

Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.

Rhea-AI Summary

BrainsWay (BWAY) reported third-quarter 2026 revenue of $18.1 million, up 34% from the same period a year earlier. Operating income rose 107% to $2.6 million, with margin increasing to 14% from 9%. Net income increased 42% to $2.2 million. Adjusted EBITDA, a profit measure excluding specified expenses and income, rose approximately 92% to $3.9 million.

Remaining performance obligations, representing contracted future revenue, increased 31% year over year to approximately $85 million. System shipments rose 44% to 130. Operating cash flow totaled $6.183 million, versus $1.386 million a year earlier. Cash, short-term deposits and restricted cash totaled $63.4 million at September 30, 2026. BrainsWay expects full-year revenue, operating income margin and adjusted EBITDA at the upper end of prior guidance, with potential to modestly exceed it. A post-quarter collaboration with Inland Psychiatric Medical Group includes a multisystem order.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary

BrainsWay (BWAY) announced a collaboration with Mindful Health Solutions aimed at expanding access to noninvasive mental health treatments. The companies aim to expand access to BrainsWay Deep TMS and the recently FDA-cleared accelerated SWIFT treatment protocol. They also plan to explore integrating Neurolief’s Proliv Rx at-home neuromodulation therapy into patient care pathways.

Planned joint initiatives include physician education, clinical awareness activities and research into combined treatment approaches. Radial Health acquired Mindful Health Solutions’ managed services organization in August; the combined management company operates under the Radial name. Separately, BrainsWay completed a recent $0.8 million follow-on equity investment in the management services organization serving the Texas-based Heading Health clinic network.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
partnership
-
Rhea-AI Summary

BrainsWay (BWAY) will report its third-quarter 2026 financial results before U.S. markets open on November 10, 2026.

The company will discuss results and operations on an English conference call and webcast at 8:30 AM Eastern Time that day. A Hebrew webcast is scheduled for November 11 at 11:00 AM Israeli Daylight Time. The English webcast replay will remain available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
earnings date
Rhea-AI Summary

BrainsWay (BWAY) expanded U.S. insurance coverage for its Deep TMS treatment for obsessive compulsive disorder to more than 118 million Americans. The expansion reflects additional medical policies providing access to the treatment.

Deep TMS, a noninvasive brain stimulation therapy, is FDA-indicated as an adjunct treatment for adults with obsessive compulsive disorder (OCD). BrainsWay plans to continue working with insurers and healthcare providers to broaden coverage and reduce treatment barriers. The expansion follows a recently announced coverage increase for its accelerated SWIFT protocol for major depressive disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
-
Rhea-AI Summary

BrainsWay (BWAY) announced a collaboration with Inland Psychiatric Medical Group that includes an order for multiple Deep TMS systems. The systems are planned for installation at IPMG clinics in Southern California. The collaboration also includes exploring scientific, clinical and research projects aimed at expanding applications of interventional psychiatry and mental health care.

IPMG provides psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment and clinical research. BrainsWay’s Deep TMS, a treatment that uses magnetic pulses to stimulate brain networks, is currently FDA-cleared for major depressive disorder with and without anxiety symptoms, obsessive-compulsive disorder and smoking addiction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
partnership
-
Rhea-AI Summary

BrainsWay (BWAY) announced expanded U.S. medical policy coverage for its SWIFT Accelerated Deep TMS protocol, a noninvasive brain stimulation treatment.

Over 70 million covered lives in the U.S. now have access to policies covering SWIFT. Favorable policy changes also extend to Deep TMS generally, including treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay said it continues educating stakeholders about Deep TMS with the goal of increasing coverage and patient access to care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.01%
Tags
none
Rhea-AI Summary

BrainsWay (BWAY) reported peer-reviewed pilot-study results of its Deep TMS technology in patients with Major Depressive Disorder and early-stage Alzheimer’s disease.

The 12-patient study delivered 36 Deep TMS sessions using the H1 and H7 coils and showed an 83.3% response rate (≥50% PHQ‑9 reduction) and a 50% remission rate (PHQ‑9 ≤4) in depressive symptoms. Quantitative EEG analyses indicated reduced delta power in the right temporal lobe and increased alpha coherence between several frontal and temporal sites, suggesting modulation of brain activity and connectivity patterns linked to Alzheimer’s disease. Results were published in the Journal of Geriatric Psychiatry and Neurology, and BrainsWay stated that further controlled clinical research is required. Deep TMS is not FDA‑cleared for treating Alzheimer’s disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

BrainsWay (NASDAQ & TASE: BWAY) reported new peer-reviewed data from a secondary analysis of a multisite randomized trial of Deep TMS in Major Depressive Disorder, published in the Journal of Affective Disorders. The analysis showed that, among 89 patients, those exhibiting suicidal ideation (SSI>0) fell from 22.5% (20/89) at baseline to 6.7% (6/89) after 6 weeks, a 70% relative reduction. Median time to improvement in suicidality was 10 days with the SWIFT accelerated Deep TMS protocol versus 13 days with the standard once-daily protocol, a statistically significant difference. According to BrainsWay, these findings align with other 2026 publications suggesting TMS is associated with reduced suicidal ideation, though Deep TMS is FDA-cleared only for MDD, not for treating or preventing suicidal ideation or behavior.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.70%
Tags
none
-
Rhea-AI Summary

BrainsWay (NASDAQ & TASE: BWAY) reported record Q2 2026 revenue of $17.1 million, up 35% year-over-year, with operating income rising to $2.4 million and net income to $2.7 million. Adjusted EBITDA increased 141% to $3.5 million, reflecting a 20% margin.

The company shipped a record 125 Deep TMS systems in the quarter, a 42% increase, bringing the installed base to about 1,949. Remaining performance obligations grew 30% to $80.4 million. BrainsWay generated $6.3 million in operating cash flow and held about $62.4 million in cash and restricted cash at June 30, 2026.

For full-year 2026, BrainsWay raised revenue guidance to $68–$70 million and Adjusted EBITDA guidance to $13–$14 million, implying anticipated revenue growth of roughly 30%–34% and Adjusted EBITDA growth of about 90%–100% versus 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.81%
Tags
Rhea-AI Summary

BrainsWay (NASDAQ & TASE: BWAY) will report its second quarter 2026 financial results and operational highlights before U.S. market open on Wednesday, August 12, 2026. An English conference call and webcast will be held at 8:30 AM Eastern Time, with a separate Hebrew webcast on Thursday, August 13, 2026 at 11:00 AM Israeli Daylight Time. The English webcast replay will be available for 30 days on BrainsWay’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.59%
Tags
earnings date

FAQ

What is the current stock price of Brainsway (BWAY)?

Brainsway (BWAY) last closed at $8.98.

What is the market cap of Brainsway (BWAY)?

The market cap of Brainsway (BWAY) is approximately $361.5M.